MannKind Corporation (MNKD)

Over the past six months, MannKind's stock price has experienced fluctuations, reaching a new 52-week high in January 2026. In Q3 2025, MannKind reported an EPS of $0.03, surpassing estimates, with revenue increasing by 17.1% year-over-year, contributing to an 8% rise in shares. In Q2 2025, total revenues increased by 6% year-over-year. The acquisition of scPharmaceuticals in October 2025 is expected to accelerate revenue growth. There was insider selling by CEO Michael Castagna and EVP Sanjay R. Singh in December and November 2025, respectively. As of January 2026, analysts have a "Moderate Buy" consensus rating for MannKind, with an average 12-month price target of $10.06.

Explicit seasonal demand patterns for MannKind's products are not clearly detailed. Tyvaso DPI has shown increased patient demand, contributing significantly to royalty revenues. Afrezza has experienced higher demand and price, leading to increased net revenue. V-Go has seen a decrease in net revenue due to lower demand, as the product is no longer actively promoted by the sales force.

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, operating within the Biotechnology and Pharmaceutical industry. The company's mission is to enhance patient outcomes and quality of life through novel drug formulations and delivery technologies. Its major products include Afrezza, an ultra-rapid-acting inhaled insulin; V-Go, a wearable insulin delivery device; Tyvaso DPI, used for the treatment of pulmonary arterial hypertension; FUROSCIX, an autoinjector for the treatment of fluid overload; and pipeline products like MNKD-101, MNKD-201, and MNKD-301.

MannKind Corporation is headquartered in Danbury, Connecticut, and maintains a manufacturing facility in the same state. The company sells its products primarily within the United States, with supply and distribution agreements for Afrezza in Brazil with Biomm S.A. and in India with Cipla Ltd.

MannKind's brand reputation has been influenced by its advancements in product development and strategic initiatives. The company's focus on patient-centric solutions and innovative inhaled therapies contributes positively to its reputation, as does the acquisition of scPharmaceuticals and progress in clinical trials. A challenge for Afrezza's broader adoption is overcoming historical safety perceptions surrounding inhaled insulin. MannKind has been noted to underperform its industry peers in news mentions.

MannKind Corporation's ownership structure includes institutional, insider, and retail investors. Institutions hold a significant portion of the stock, with major institutional shareholders including BlackRock, Inc., Vanguard Group Inc., Rubric Capital Management LP, State Street Corp, and Geode Capital Management, Llc. Alfred E. Mann, the company's founder, was a substantial individual shareholder. Insiders own a smaller percentage, with recent insider selling by the CEO and an EVP.